Ekf Diagnostics Dividends - EKF

Trade Now

Capital at risk

Stock Name	Stock Symbol	Market	Stock Type
Ekf Diagnostics Holdings Plc	EKF	London	Ordinary Share

	Price Change	Price Change %	Stock Price	Last Trade
	-0.40	-1.0%	39.60	14:27:22

Open Price	Low Price	High Price	Close Price	Previous Close
40.00	39.60	40.70		40.00

more quote information »

Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Ekf Diagnostics EKF Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
05/05/2021	Interim	GBX	1.1	01/07/2020	31/12/2020	04/11/2021	05/11/2021	01/12/2021	2.1
14/09/2020	Interim	GBX	1	30/12/2019	30/06/2020	04/11/2020	05/11/2020	01/12/2020	0

Top Dividend Posts

Top Posts
Posted at 27/9/2022 08:16 by wan EKF's Advanced Diagnostic Laboratory (ADL) website homepage has been updated - hTTps://www.adlhealth.com/ ADL has also launched their comprehensive PreCheck™ Prenatal NIPT national screening webpage - Recall the following from the Interims - At the beginning of the year, we signed a strategic partnership agreement with Yourgene Health plc ("Yourgene") to offer a non-invasive prenatal test ("NIPT") service from our accredited US laboratory. We expect this service to launch in October 2022 and we believe this is an exciting growth opportunity. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Half-year-Report/89095407 And from the Strategic partnership agreement with Yourgene - The adoption for NIPT in the US has accelerated with recent guidelines issued from American College of Obstetricians and Gynaecologists ("ACOG") recommending NIPT to be made available to all pregnant women(1) . As part of the agreement, Yourgene will provide ADL Health with access to YGEN's proprietary reagents and NGS analysis software as part of a technology transfer agreement to enable ADL Health to build a rapid turnaround NIPT service for the US market. Currently, a majority of US NIPT samples are sent to large central testing laboratories, which are costly and experience lengthy lead times . In contrast, the new ADL NIPT service will offer rapid turnaround times as the NIPT workflow can be performed in as little as 48 hours, enabling a competitive response and allowing both EKF and Yourgene to gain traction in this large growing market. According to third party forecasts, the US NIPT market is expected to reach a valuation of USD 2.5 Billion by 2028(2). hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Strategic-partnership/87033674 PRECHECK™ PRENATAL NIPT Enhancing existing prenatal screening pathways for pregnant women with fast, reliable results while reducing the need for invasive tests and the associated patient stress and anxiety. Non-Invasive Prenatal Testing hTTps://www.adlhealth.com/products/precheck/ Read Full Thread Follow Reply
Posted at 21/9/2022 10:57 by wan I note the article and comment from the IC below, which has a hold recommendation. One would assume though from the following comment "The company is outperforming compared with pre-pandemic figures, but it must articulate a new direction", that whilst EKF is indeed outperforming, the articulate part was surely made/published prior to the live webcast, because in my view, the management articulated very well indeed regarding the overall business and indeed the new direction. EKF Diagnostics initiates post-Covid transformation The company is outperforming compared with pre-pandemic figures, but it must articulate a new direction. September 20, 2022 By Jennifer Johnson hTTps://www.investorschronicle.co.uk/news/2022/09/20/ekf-diagnostics-initiates-post-covid-transformation/ The IC also refer to "The transition of Contract Manufacturing and Laboratory Services into non-COVID-related revenues is our key challenge." which was stated in the Half Year Report. However, that challenge, when reading only the results, didn't come across in the same way as from the webinar and Interim Presentation, which appeared quite upbeat in terms of the progress to date and the future prospects. EKF is indeed transitioning though, but to an increasingly sophisticated and diverse global medical diagnostic business, and positioning EKF for very much long-term sustainable growth. My questions were apparently submitted too late to be considered as part of the Q&A (I was unable to attend the live event). Interim Results Presentation September 2022 - hTTps://www.ekfdiagnostics.com/res/EKF%202022%20Interims%20Investor%20Pres%20FINAL.pdf Read Full Thread Follow Reply
Posted at 08/9/2022 07:59 by wan A couple of items that caught my attention - Our team will be presenting EKF Link and our Diabetes monitoring devices at the event Point of Care Innovations in Bristol, UK. Don't miss out! Join us at Point of Care Innovations on 20 September 2022 to learn all about the EKF Diagnostics point-of-care range including HbA1c analyzers, glucose analyzers and hemoglobin analyzers for use in the screening, monitoring and diagnosis of patients as well as rapid tests for pregnancy and common infectious diseases. EKF's point-of-care (PoC) analyzers are designed for use within doctors' surgeries, clinics, hospitals and laboratories to provide fast and accurate results at an affordable price. By definition, PoC testing is carried out in the presence of the patient allowing open dialogue between them and the practitioner. In this way patients benefit from receiving medical advice during the course of a single visit. All EKF point-of-care analyzers and consumables are CE marked; there are also CLIA waived products within the portfolio. hTTps://www.linkedin.com/posts/ekf-diagnostics_poct-pointofcaretesting-ekfdiabetescare-activity-6973270062992343040-R5oZ?utm_source=share&utm_medium=member_desktop Given EKF's range of point-of-care analysers, their growing portfolio provides food for thought regarding the following - Sep 7, 2022 Pharmacy-Based Testing Sees Growing Legislative, Commercial Momentum Changing business models and new legislative initiatives are driving point-of-care testing in pharmacies in the wake of the COVID-19 pandemic. hTTps://www.360dx.com/point-care-testing/pharmacy-based-testing-sees-growing-legislative-commercial-momentum Read Full Thread Follow Reply
Posted at 05/8/2022 10:17 by wan Hi James, I don't disagree regarding the share performances, nor the fact it's 'hopefully' still too early to judge those spinout shares. But as I said back in April, for those of us still holding the extended family of EKF stocks, on the one hand we are still better off than we were without the in-specie shares (unless you participated directly), but the overall performance thus far is more than disappointing, to say the least! I also suggested that given the market backdrop, going forwards, one wonders if the spin-off model has any immediate candidates, or indeed any further legs at all. In my view, Verici and Trellus (trading at near or below cash) are more likely to be acquired than require additional funding, but only time will tell. With regard to Verici, with strong IP and scientifically validated tests, it is worth noting that other related transplant players have IP issues, but plenty of cash and/or the financial firepower on tap. On the one hand the market is hardly conducive or receptive to further spinouts atm, and perhaps especially so given the dire performance of the previous spinout shares. To my mind, one or more of those spinouts will have to perform and deliver before there is any appetite for any further opportunities. Personally, I would like to see EKF invest and develop their own IP, or at least the development of proprietary products. In this regard, I repeat in part what I stated back in May as a result of an answer to my question at the AGM - EKF are not developing proprietary tests/assays per se (or at least not yet), they will however produce both proprietary EKF enzymes as well as third party enzymes that can be produced in bulk scale for mass production of test kits, such as molecular testing, and indeed in other application areas too e.g. buffer formulations (watch this space👀). So, proprietary, high margin, enzymes might be an example of an aspect that's underappreciated, as clearly, such enzymes could generate significant value, as well as providing potential to increase EKF's attraction to new and existing partners (already happening in my view), and as well as extending EKF's own moat. In this regard, the partnership with ABEC to deliver customised, large-scale bioprocess equipment to EKF's specific manufacturing requirements is perhaps particularly worthy of note. Elsewhere, I note development of a unique fermentation platform to 'sustainably' produce high-quality molecules through fermentation. Such 'bespoke and specialised' fermentation platforms will enable a consistent, scalable, and reliable supply of high-quality functional molecules. In short, EKF are leveraging their extensive manufacturing capabilities and many years of experience to respond to demand-driven opportunities in a very specialised, attractive, high growth areas. With the recent Trading Update providing increased confidence in terms of core business recovery, expansion, and indeed the delivery of the Growth Strategy. Read Full Thread Follow Reply
Posted at 03/8/2022 11:51 by rivaldo Techinvest have published their new issue, so it should be OK to copy their Buy update on EKF from the July issue: "EKF Diagnostics EKF has announced the intention to distribute shares in its investment, Verici Dx, to the company’s shareholders who will receive one investment share for every 50 ordinary shares held in EKF. In order to maintain an orderly market in Verici’s shares following the distribution, the shares will be held in trust for shareholders for a period of a year. During the lock-up period, EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Verici investment shares. Verici is a developer of advanced clinical diagnostics for organ transplant. The company is one of three business that have emerged so far from EKF’s preferred partnership agreement to develop healthcare technologies alongside Mount Sinai Health System. The other businesses are Renalytix, which is currently trading on AIM and Nasdaq, and Trellus Health. Both Trellus and Verici are listed on AIM. EKF reported owning around 5.7% of Verici’s shares at the time of the company’s final results announcement in March. The partnership with Mount Sinai is proving fruitful and represents an asset that investors may be overlooking when valuing shares in EKF. We feel that the company’s core business alone is somewhat undervalued by the current share price. Stripping out net cash of 4.6p per share, the shares trade on a prospective P/E of 14.1 for the current year, falling to 11.4 for fiscal 2023. Add in the projected value of the business investments in the Mount Sinai partnership and the stock looks excessively neglected. Buy." Read Full Thread Follow Reply
Posted at 01/7/2022 14:23 by wan 'On plan' news - Industry News: EKF to highlight specific glycemic control marker at AACC 2022 EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637 30 Jun 2022 EKF Diagnostics, a global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients. Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material. “The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics. Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure, and effective POC testing using analyzers in many differing locations. EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories, and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely. EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities. hTTps://www.selectscience.net/industry-news/ekf-to-highlight-specific-glycemic-control-marker-at-aacc-2022/?artID=57786 Recall from the EKF Link RNS - The development and launch of EKF Link has been driven by customer demand and designed in partnership with hospital POC managers to ensure the software meets their specific needs. EKF Link provides the Company with improved competitive positioning for future POC contract tenders and new accounts, and increases the attractiveness of the EKF product portfolio to existing customers against currently available technologies. Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance our POC analyser portfolio and technology offering, we are pleased to announce that we have successfully launched EKF Link enabling practitioners to analyse their patients' results remotely, easily and securely. EKF Link provides our POC diagnostic devices with a connectivity advantage which positions us well for tenders and new accounts. This is particularly true in Europe and North America, where a connectivity solution is commonly a part of the specification. EKF Link has the added benefit that it can be installed wherever it is needed, on a PC or a central server, allowing hospitals and laboratories, technicians and clinicians to access results from various settings, reducing workload whilst increasing the security of handling patient data. "This new product launch shows our responsiveness to our customer base and increasing demand for data management capabilities. It extends the utility of our installed instrument base and provides EKF with a key advantage for further new business opportunities." hTTps://www.ekfdiagnostics.com/launch-of-ekf-link.html Read Full Thread Follow Reply
Posted at 31/5/2022 05:29 by wan EKF Diagnostics : launches middleware connectivity solution for POC analyzers and data management 05/30/2022 EKF Diagnostics announces the launch of its newEKF Link digital connectivity solution for the secure management of point-of-care (POC) analyzers and associated data on one centralized platform. An open, flexible solution, EKF Link middleware can be interfaced to all vendors' POC analyzers, including EKF's own portfolio, to enable real-time remote management of data, such as patient test results, QC results, operator management and analyzer configuration. "We designed EKF Link working together with hospital POC managers to ensure that our new middleware connectivity solution would meet their specific needs for a single, comprehensive and flexible platform to centrally manage all of their POC analyzers plus data generated," said Jo Nicol, Head of IT Solutions, EKF Diagnostics. "Our new EKF Link software delivers this essential digital connectivity with traceability that is increasingly required for safe, secure and effective POC testing using analyzers in many differing locations." Full release - hTTps://www.ekfdiagnostics.com/ekf-launches-poc-connectivity-solution.html Connect all of your analyzers on one software platform EKF Link is a middleware solution for healthcare providers to manage all of their Point of Care analyzers and the generated data on one centralized platform. EKF Link is a flexible, open solution that can be interfaced to any vendor’s Point of Care analyzer to permit the real-time management of data including patient test results, QC results, operator management and analyser configuration. EKF Link enables the transfer of data from the analyzer to the hospital or laboratory database for subsequent processing. hTTps://www.ekfdiagnostics.com/ekf-link.html Read Full Thread Follow Reply
Posted at 19/5/2022 07:58 by wan AGM commentary. As mentioned previously, there was an excellent range of questions submitted in advance (by myself and others) and asked during the AGM. Several questions and answers particularly stood out, especially in terms of the answers given and are worthy of highlighting by way of a summary from my very quickly taken notes (which do not cover everything) and must be taken on the basis they may not be a perfect reflection (audio was also not always perfect). A question was raised regarding Oragenics. Oragenics has recently been focusing on vaccines. However, whilst they are still pursuing vaccines for COVID they have also recommenced work with EKF on their novel Lantibiotics aimed addressing antibiotic resistant infections - hTTps://www.oragenics.com/technology-pipeline/lantibiotics A question was asked about margins on EKF's Fermentation products. The molecular fermentation products have a 'materially' higher margin that EKF's current point of care products (I am not going to put the margin referred to on here), such that it will be a significant driver of EKF's growth over the next few years. One of my questions - Is there any interest from private or public sector customers in providing supply chain resilience and preparedness in terms of molecular sample collection products for future pandemics/health emergencies? Yes, EKF are also actively tendering for several government contracts. One of my questions - Are there any expansion plans for veterinary applications/tests? EKF are already in the veterinary market with one test, but will be launching a new product for Lactate testing next month, and expanding their offering further with other products. The CEO described the veterinary market as very interesting, which is not as highly regulated as EKF's other healthcare markets. There was a question regarding an apparently recent note from Investec, that 'apparently' has a price target for EKF of 94 pence. This question was not directly answered (obviously), but provides food for thought if correct. One of my questions - Can you provide an update on the development of the EKF Response aimed at Sepsis testing in critical care settings? Ongoing development, if all continues to go well, then launch expected in 2023. I may be able to add a few other aspects in due course. Read Full Thread Follow Reply
Posted at 15/4/2022 10:57 by wan Stoxman...My thoughts, for what they are worth. With the general cloud hanging over the growth/biotech sector, perhaps exemplified by the fact that there is apparently a record £1.9tn on deposit in the UK at a time when deposit rates are at a record low, it's definitely risk off, but one could also argue that there is potentially a lot of dry powder in the wings. For those of us still holding the extended family of EKF stocks, on the one hand we are still better off than we were without the in-specie shares, but the overall performance thus far is disappointing to say the least. With regard to Verici in particular, clearly some investors preferred to sell rather than hold post the lock-up period, and given the dire performance, it appears they have been proven right so far. And it would also appear that the performance of Trellus is perhaps indicating that a similar post lock-up situation could occur starting next month. Personally speaking, I cooled on Trellus a while back given that they appear to be delayed, and indeed the number of companies focusing on similar/overlapping areas is presenting for a huge amount of competition. Given the unrelenting selling in Verici post lock-up, not to mention the overall performance across the holdings, and indeed the market backdrop, going forwards one wonders if the spin-off model has any immediate candidates/legs, or will indeed follow similar paths, especially if Trellus follows similar price action to Verici. In my view, Verici is in a more advanced and stronger position. There are larger players that could not only accelerate commercialisation, but that are arguably in need Verici's differentiated and litigation free products, which are underpinned by extensive scientific research and strong IP. At the very least, I am thus expecting partnerships, and I would not exclude Verici being acquired outright. A partnership deal, or a catalyst breakthrough in any one of the family could have a positive effect on the others, but we have been expecting that from Renalytix for quite some time, and clearly analysts have finally run out of patience with the management at Renalytix, which is not completely unfair, but I can see both sides of the argument. Again, in my view, it's far too early to judge the new management team, but clearly the market does not like the current forecasts, as exampled below, albeit it I think James had already highlighted such coverage a few weeks ago, so I am not sure how up to date/relevant it actually is - Some EKF Diagnostics Holdings plc (LON:EKF) Analysts Just Made A Major Cut To Next Year's Estimates By Simply Wall St Published April 14, 2022 hTTps://simplywall.st/stocks/gb/healthcare/aim-ekf/ekf-diagnostics-holdings-shares/news/some-ekf-diagnostics-holdings-plc-lonekf-analysts-just-made What I did find interesting in the above piece, was the graph, which clearly shows the expected revenue decline. Nonetheless, when you factor-out the COVID related bump, revenue growth in 2023 is quite a lot higher than pre-pandemic revenues, and overall the forecast is on a not too shabby upward trajectory. According to the chart, revenues and other financial metrics for 2024 are forecast to be similar to the COVID-boosted revenues for 2021. If we were to assume that a similar share price can be achieved to the peak in 2021 of over 80p, some would suggest that, for the patient investor, the current share price is offering a decent entry point and a dividend yield of over 3%. An important difference to consider though, is that the non-COVID related growth in revenues will be far more sustainable! I am hopeful that managements guidance has been conservative (EKF's Growth Strategy indicated such with regard to fermentation), as obviously it would be much better to resume a period of beating analysts expectations, especially with revenue increases that are sustainable. Read Full Thread Follow Reply
Posted at 05/4/2022 08:10 by buywell2 6M buybacks and only another 3M left is that not correct Then quite a long wait for the next tranche if it gets the nod Interestingly SBI have not announced an initial/interim buyback program like EKF What say you wan ? 05 Apr 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 04 Apr 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 01 Apr 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 31 Mar 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 30 Mar 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 29 Mar 2022 7:01 am RNS Factsheet EKF Diagnostics Hldg (EKF) Share Buyback Programme 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Final Results Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

EKF

Ekf Diagno..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20221004 13:42:24